Society for Clinical Research Sites Welcomes Myoderm as New Global Impact Partner


Applied Clinical Trials

Ellicott City, M.D., May 11, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year collaboration with Myoderm, a global leader and specialist in sourcing, distribution, and management of comparator drugs and other pharmaceutical products and supplies for clinical research. Myoderm will participate as a Global Impact Partner (GIP) and align with sponsors, CROs and other industry solution providers who share an ongoing commitment to promoting site sustainability across the clinical trials landscape.

“SCRS is pleased to welcome Myoderm as our newest Global Impact Partner,” comments Christine Pierre, SCRS President. “Collaboration with Myoderm will incite dialogue around drug and product sourcing for clinical trials; factors which can affect individual sites. Myoderm has supply chain experience that factors into trial design, and can be shared to gain efficiencies in the processes currently being used.”

“We are honored to be a part of and collaborate with such an innovative organization and group of professionals,” Michael Cohen, Managing Director of Myoderm, remarks. “For more than 25 years we have focused on developing clinical trial supply solutions for sponsors, CROs and research sites alike. We see this partnership as an opportunity to make further advancements to the supply chain, alleviating pressure on research sites and positively impacting patients that benefit from new therapies being developed.”

As a Global Impact Partner (GIP), Myoderm will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.